Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Cancer Immunology, Immunotherapy
Published in: Cancer Immunology, Immunotherapy 12/2009

01-12-2009 | Symposium in Writing

Mechanisms of murine dendritic cell antitumor dysfunction in aging

Authors: Annabelle Grolleau-Julius, Lisa Abernathy, Erin Harning, Raymond L. Yung

Published in: Cancer Immunology, Immunotherapy | Issue 12/2009

Login to get access

Abstract

Effective cancer immunotherapy depends on the body’s ability to generate tumor antigen-presenting cells and tumor-reactive effector lymphocytes. As the most potent antigen presenting cells (APCs), dendritic cells (DCs) are capable of sensitizing T cells to new and recall antigens. Clinical trials of antigen-pulsed autologous DCs have been conducted in patients with a number of hematological and solid cancers, including malignant melanoma, lymphoma, myeloma, and non-small cell lung cancer. These studies suggest that antigen-loaded DC vaccination is a potentially safe and effective cancer therapy. However, the clinical results have been variable. Since the elderly are preferentially affected by diseases targeted by DC-directed immunotherapy, it is quite striking that few studies to date have focused on the effect of aging on DC function, a key aspect of optimal immunotherapy design in an aging population. In the present paper, we will discuss the consequences of aging on murine bone marrow-derived DC function and their use in cancer immunotherapy.
Literature
1.
Agrawal A, Agrawal S, Cao JN, Su H, Osann K, Gupta S (2007) Altered innate immune functioning of dendritic cells in elderly humans: a role of phosphoinositide 3-kinase-signaling pathway. J Immunol 178:6912–6922PubMed
2.
Agrawal A, Agrawal S, Tay J, Gupta S (2008) Biology of dendritic cells in aging. J Clin Immunol 28:14–20PubMedCrossRef
3.
Chen J, Mo R, Lescure PA, Misek DE, Hanash S, Rochford R, Hobbs M, Yung RL (2003) Aging is associated with increased T-cell chemokine expression in C57BL/6 mice. J Gerontol A Biol Sci Med Sci 58:975–983PubMed
4.
5.
Flamand V, Sornasse T, Thielemans K, Demanet C, Bakkus M, Bazin H, Tielemans F, Leo O, Urbain J, Moser M (1994) Murine dendritic cells pulsed in vitro with tumor antigen induce tumor resistance in vivo. Eur J Immunol 24:605–610PubMedCrossRef
6.
Fulop T, Larbi A, Wikby A, Mocchegiani E, Hirokawa K, Pawelec G (2005) Dysregulation of T-cell function in the elderly: scientific basis and clinical implications. Drugs Aging 22:589–603PubMedCrossRef
7.
Gao FG, Khammanivong V, Liu WJ, Leggatt GR, Frazer IH, Fernando GJ (2002) Antigen-specific CD4+ T-cell help is required to activate a memory CD8+ T cell to a fully functional tumor killer cell. Cancer Res 62:6438–6441PubMed
8.
Geiger JD, Wagner PD, Shu S, Chang AE (1992) A novel role for autologous tumour cell vaccination in the immunotherapy of the poorly immunogenic B16-BL6 melanoma. Surg Oncol 1:199–208PubMedCrossRef
9.
Geijtenbeek TB, Torensma R, van Vliet SJ, van Duijnhoven GC, Adema GJ, van Kooyk Y, Figdor CG (2000) Identification of DC-SIGN, a novel dendritic cell-specific ICAM-3 receptor that supports primary immune responses. Cell 100:575–585PubMedCrossRef
10.
Gijzen K, Tacken PJ, Zimmerman A, Joosten B, de Vries IJ, Figdor CG, Torensma R (2007) Relevance of DC-SIGN in DC-induced T cell proliferation. J Leukoc Biol 81:729–740PubMedCrossRef
11.
Grolleau-Julius A, Garg MR, Mo R, Stoolman LL, Yung RL (2006) Effect of aging on bone marrow-derived murine CD11c+ CD4-CD8alpha-dendritic cell function. J Gerontol A Biol Sci Med Sci 61:1039–1047PubMed
12.
Grolleau-Julius A, Harning EK, Abernathy LM, Yung LR (2008) Impaired dendritic cell function in aging leads to defective antitumor immunity. Cancer Res
13.
Grolleau A, Sloan A, Mule JJ (2005) Dendritic cell-based vaccines for cancer therapy. Cancer Treat Res 123:181–205PubMedCrossRef
14.
Gunn MD, Kyuwa S, Tam C, Kakiuchi T, Matsuzawa A, Williams LT, Nakano H (1999) Mice lacking expression of secondary lymphoid organ chemokine have defects in lymphocyte homing and dendritic cell localization. J Exp Med 189:451–460PubMedCrossRef
15.
Krishnan L, Sad S, Patel GB, Sprott GD (2000) Archaeosomes induce long-term CD8 + cytotoxic T cell response to entrapped soluble protein by the exogenous cytosolic pathway, in the absence of CD4+ T cell help. J Immunol 165:5177–5185PubMed
16.
Lesterhuis WJ, Aarntzen EH, De Vries IJ, Schuurhuis DH, Figdor CG, Adema GJ, Punt CJ (2008) Dendritic cell vaccines in melanoma: from promise to proof? Crit Rev Oncol Hematol 66:118–134PubMedCrossRef
17.
18.
Montoya MC, Sancho D, Bonello G, Collette Y, Langlet C, He HT, Aparicio P, Alcover A, Olive D, Sanchez-Madrid F (2002) Role of ICAM-3 in the initial interaction of T lymphocytes and APCs. Nat Immunol 3:159–168PubMedCrossRef
19.
Nencioni A, Grunebach F, Schmidt SM, Muller MR, Boy D, Patrone F, Ballestrero A, Brossart P (2008) The use of dendritic cells in cancer immunotherapy. Crit Rev Oncol Hematol 65:191–199PubMedCrossRef
20.
Paglia P, Chiodoni C, Rodolfo M, Colombo MP (1996) Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo. J Exp Med 183:317–322PubMedCrossRef
21.
22.
Porgador A, Gilboa E (1995) Bone marrow-generated dendritic cells pulsed with a class I-restricted peptide are potent inducers of cytotoxic T lymphocytes. J Exp Med 182:255–260PubMedCrossRef
23.
Randolph GJ, Angeli V, Swartz MA (2005) Dendritic-cell trafficking to lymph nodes through lymphatic vessels. Nat Rev Immunol 5:617–628PubMedCrossRef
24.
Sharma S, Dominguez AL, Lustgarten J (2006) Aging affect the anti-tumor potential of dendritic cell vaccination, but it can be overcome by co-stimulation with anti-OX40 or anti-4-1BB. Exp Gerontol 41:78–84PubMedCrossRef
25.
Shi M, Bi X, Xu S, He Y, Guo X, Xiang J (2005) Increased susceptibility of tumorigenicity and decreased anti-tumor effect of DC vaccination in aged mice are potentially associated with increased number of NK1.1+ CD3+ NKT cells. Exp Oncol 27:125–129PubMed
26.
Shurin MR, Shurin GV, Chatta GS (2007) Aging and the dendritic cell system: implications for cancer. Crit Rev Oncol Hematol 64:90–105PubMedCrossRef
27.
Steinman RM (1991) The dendritic cell system and its role in immunogenicity. Annu Rev Immunol 9:271–296PubMedCrossRef
28.
Villadangos JA, Schnorrer P (2007) Intrinsic and cooperative antigen-presenting functions of dendritic-cell subsets in vivo. Nat Rev Immunol 7:543–555PubMedCrossRef
29.
Wick G, Grubeck-Loebenstein B (1997) The aging immune system: primary and secondary alterations of immune reactivity in the elderly. Exp Gerontol 32:401–413PubMedCrossRef
Metadata
Title
Mechanisms of murine dendritic cell antitumor dysfunction in aging
Authors
Annabelle Grolleau-Julius
Lisa Abernathy
Erin Harning
Raymond L. Yung
Publication date
01-12-2009
Publisher
Springer-Verlag
Published in
Cancer Immunology, Immunotherapy / Issue 12/2009
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI
https://doi.org/10.1007/s00262-008-0636-9

Other articles of this Issue 12/2009

Cancer Immunology, Immunotherapy 12/2009 Go to the issue

Original Article

Identification and modification of an HLA-A*0201-restricted cytotoxic T lymphocyte epitope from Ran antigen

Original Article

Downregulation of interleukin-7 and hepatocyte growth factor in the thymic microenvironment is associated with thymus involution in tumor-bearing mice

Original Article

Rejection of intradermally injected syngeneic tumor cells from mice by specific elimination of tumor-associated macrophages with liposome-encapsulated dichloromethylene diphosphonate, followed by induction of CD11b+/CCR3−/Gr-1− cells cytotoxic against the tumor cells

Original article

2B4 (CD244) signaling via chimeric receptors costimulates tumor-antigen specific proliferation and in vitro expansion of human T cells

Original Article

A genetic variant of immunoglobulin γ2 is strongly associated with immunity to mucin 1 in patients with breast cancer

Symposium in Writing

Use of CD40L immunoconjugates to overcome the defective immune response to vaccines for infections and cancer in the aged
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits